Journal of Thrombosis and Thrombolysis最新文献

{"title":"Protein carbonylation as a modulator of fibrin clot properties in thyroid disorders: impact of therapy.","authors":"Kamila W Undas, Julianna Dąbrowa, Joanna Natorska, Piotr Mazur, Alicja Hubalewska-Dydejczyk, Anetta Undas","doi":"10.1007/s11239-025-03180-5","DOIUrl":"https://doi.org/10.1007/s11239-025-03180-5","url":null,"abstract":"<p><p>Protein carbonylation (PC), a marker of oxidative stress, was shown to be elevated in both hyperthyroid and hypothyroid disorders. These conditions are associated with unfavorable fibrin clot properties. We sought to investigate whether elevated PC is associated with prothrombotic markers in hyperthyroid and hypothyroid individuals before and following effective therapy. We studied 31 hyperthyroid, 29 hypothyroid patients, and 29 sex- and age-matched controls. Along with plasma total PC content, we measured fibrin clot properties (fibrin clot permeability, K_s; clot lysis time, CLT), fibrinolysis proteins, and thrombin generation before and after 3-month successful therapy. Hyperthyroid patients had a tendency to higher PC (+ 9.1%; p = 0.05), while hypothyroid individuals had 17.2% higher PC (p = 0.01) compared with controls, without any difference between the patient groups. Pre-treatment PC inversely correlated with K_s in both hyper- (R=-0.425, p = 0.017) and hypothyroid (R=-0.510, p = 0.005) individuals, while solely in hyperthyroid patients PC was associated with CLT (R = 0.556, p = 0.001), but not with fibrinolysis inhibitors, or other hemostatic markers. On-treatment PC, which decreased by 19.6% (p < 0.001) in hyperthyroid and by 23.4% (p < 0.001) in hypothyroid patients reaching the control levels, was associated with K_s (R=-0.401, p = 0.031) and CLT (R = 0.537, p = 0.003) only in the hypothyroid group. In hyper- and hypothyroid patients elevated PC may contribute to formation of more compact fibrin clot networks with impaired fibrinolysis in the former group. Reduced PC following thyroid hormone normalization maintained its impact on fibrin clot properties solely in hypothyroid patients, which indicates complex effects of oxidative stress on blood coagulation.</p>","PeriodicalId":17546,"journal":{"name":"Journal of Thrombosis and Thrombolysis","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145176252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long term anticoagulation for Catheter-Related deep vein thrombosis of the upper extremities in women with cancer: retrospective analysis of effectiveness and safety outcomes.","authors":"Chiara Cavallaro, Paolo Santini, Laura Leoni, Carolina Mosoni, Silvia D'Ambrosio, Francesco Mancinetti, Nicola Coletta, Michela Iorio, Angelo Porfidia, Alessandro D'Errico, Rosa Talerico, Roberto Pola","doi":"10.1007/s11239-025-03182-3","DOIUrl":"https://doi.org/10.1007/s11239-025-03182-3","url":null,"abstract":"<p><p>Catheter-related upper extremity deep vein thrombosis (CRT-UEDVT) is a possible complication in patients with cancer carrying a central venous catheter. Anticoagulation is the primary treatment, but optimal duration is unclear. This study evaluated effectiveness and safety of different lengths of anticoagulation in women with cancer and CRT-UEDVT. We conducted a retrospective analysis on women ≥ 18 years-old, who had active cancer and had received anticoagulant treatment for CRT-UEDVT. Effectiveness was assessed in terms of VTE recurrence and thrombosis recanalization. Safety was determined by assessing major bleedings (MB) and clinically relevant non-major bleedings (CRNMB) during treatment. A total of 113 women where included. All of them had completed at least 3 months of anticoagulant therapy, while 106 and 97 had completed 6 and 12 months of anticoagulant therapy, respectively. The median follow-up was 568.5 days (IQR 300-910). Patients primarily presented with ovarian, breast, and endometrial cancers. Anticoagulant therapy was mainly parenteral during the initial 3 months and between 3 and 6 months, shifting predominantly to direct oral anticoagulants during months 6-12. The annual VTE recurrence rate was 0.5%. The annual rate of MB and CRNMB was 1.9%. Complete thrombosis recanalization was achieved in 52.0%, 69.1%, and 87.3% of patients at 3, 6, and 12 months, respectively. Our study provides interesting insights into the management and clinical outcomes of women with cancer and CRT-UEDVT. Prospective studies are needed to fully understand advantages and disadvantages of different lengths of anticoagulation in this set of patients.</p>","PeriodicalId":17546,"journal":{"name":"Journal of Thrombosis and Thrombolysis","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145176268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Apixaban versus warfarin for treatment of venous thromboembolism in patients with severe renal impairment: a multicenter study.","authors":"Paige Hanke, Ma Emmanuelle Domingo, Ghenella Salanio, Kulsoom Ahmed, Jingyu Hu, Kristin Hendricks, Jacob Howard, Tori Hashimura, Chris Guiliano, Bradley J Haan, Tsz Hin Ng, Denise Kelley, Tamara Knight, Kathleen Koopman, Monika Obstoj, Thomas Breeden, Dumitru Sirbu, Meredith Romano, Andrew Harpenau, Rebecca Konneker, Jason Acevedo, Neil Pan, Stephanie B Edwin","doi":"10.1007/s11239-025-03162-7","DOIUrl":"https://doi.org/10.1007/s11239-025-03162-7","url":null,"abstract":"","PeriodicalId":17546,"journal":{"name":"Journal of Thrombosis and Thrombolysis","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145081088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating cfdna: A novel biomarker for preventing early recurrence in ischemic stroke.","authors":"Xinglan Li, Yongjin Yuan, Weiyao Jing, Cui Liu, Mai Wei, Qianru Liu, Xing Li, Long Wei, Xiaozheng Du, Jinhai Wang","doi":"10.1007/s11239-025-03179-y","DOIUrl":"https://doi.org/10.1007/s11239-025-03179-y","url":null,"abstract":"<p><p>Stroke is the second-leading cause of mortality and the principal contributor to long-term disability worldwide. Despite the widespread clinical implementation of secondary prevention protocols, the 90-day stroke recurrence rate remains a significant concern, particularly among patients with atherosclerosis. Mounting evidence implicates inflammatory pathways as central mediators in both atherogenesis and plaque destabilization. It is known that ischemic stroke triggers a substantial release of cell-free DNA (cfDNA) into the systemic circulation. These nucleic acid fragments can subsequently activate endothelial cells, thereby promoting atherosclerosis, and can also activate nucleotide-sensing inflammasomes within vulnerable plaques, thus triggering thrombotic cascades and early recurrent cerebrovascular events. In this review, we comprehensively examine the pathophysiological origins of cfDNA, delineate its mechanistic involvement in stroke recidivism, and evaluate current therapeutic strategies targeting cfDNA catabolism in the management of ischemic stroke, aiming to provide insights for future research in this field.</p>","PeriodicalId":17546,"journal":{"name":"Journal of Thrombosis and Thrombolysis","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145069822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment failure in patients with obesity with venous thromboembolism receiving truncated vs. recommended lead-in times with apixaban at an academic medical center.","authors":"Allison Murchison, Noah Ball, Matthew Rockhold, Benjamin Bredhold","doi":"10.1007/s11239-025-03181-4","DOIUrl":"https://doi.org/10.1007/s11239-025-03181-4","url":null,"abstract":"<p><p>Optimal lead-in duration of apixaban following a period of therapeutic parenteral anticoagulation for venous thromboembolism (VTE) has become controversial, and truncated lead-in periods accounting for parenteral therapy have been proposed in recent studies. Results from previous studies cannot be generalized to many subpopulations of interest, including patients with obesity. This study characterized recurrent VTE in patients with obesity within 6 months of apixaban initiation based on full versus truncated lead-in times following parenteral anticoagulation. This single-center, multi-site, retrospective cohort study within the West Virginia University Medicine enterprise among adult patients with obesity, defined as body mass index (BMI) of 30 kg/m² or greater, diagnosed with VTE who received apixaban following at least 48 h of parenteral anticoagulation. Truncated lead-ins were uncommon (10%). There were no significant differences in recurrent thrombosis between full and truncated lead-in cohorts [10 (4.5%) vs. 2 (8.0%); p = 0.771]. The truncated lead-in cohort was associated with longer length of stay and extended duration of parenteral anticoagulation. A truncated lead-in strategy may be reasonable for patients with obesity. Larger studies should be conducted to identify patient factors that support the use of a truncated lead-in strategy. 1) Previous studies investigating truncated lead-in times cannot be generalized to subpopulations of interest such as patients with obesity 2)Safety and efficacy outcomes are variable among the general population within previous studies 3) In clinical practice, truncated lead-in regimens are chosen for patients with longer durations of parenteral anticoagulation 4)Recurrent thrombosis rates within subpopulations who are at higher of thrombosis requires further evaluation regarding the truncated lead-in.</p>","PeriodicalId":17546,"journal":{"name":"Journal of Thrombosis and Thrombolysis","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145065001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tyrosine kinase inhibitors - balancing the haemostatic scales: a review of associated thrombosis and bleeding.","authors":"Lloyd E Butel-Simoes, Ammar Albayati, Jie Yu, Thomas Quirk, Shanathan Sritharan, Matthew French, Joshua D Bennetts, Doan T M Ngo, Aaron L Sverdlov","doi":"10.1007/s11239-025-03151-w","DOIUrl":"https://doi.org/10.1007/s11239-025-03151-w","url":null,"abstract":"<p><p>Tyrosine kinase inhibitors (TKIs) have revolutionised cancer therapy, significantly impacting survival and outcomes by targeting specific signalling pathways that are necessary for tumour survival. Despite their clinical efficacy, TKIs exhibit a complex toxicity profile. Many of the signalling pathways that are targeted by TKIs are shared with normal homeostatic processes, including those responsible for modulating thrombosis and bleeding. The risk profile of thrombosis and bleeding associated with TKIs varies considerably across agents. Multi-kinase inhibitors, particularly those targeting the breakpoint cluster regio-abelson murine leukaemia 1 gene mutation (BCR-ABL) (i.e., nilotinib and ponatinib), significantly elevate arterial thrombotic events. This thrombosis risk is driven by endothelial dysfunction, accelerated atherosclerosis, platelet hyper-reactivity, and impaired fibrinolysis. Similarly, vascular endothelial growth factor (VEGF) pathway inhibition contributes markedly to thrombotic vascular complications by reducing vasodilators like nitric oxide and promoting pro-thrombotic endothelial environments. TKIs targeting the VEGF receptor (VEGFR-TKIs) (i.e., sunitinib and regorafenib) and brutons tyrosine kinase (BTK) inhibitors (i.e., ibrutinib), increase bleeding risk through platelet dysfunction, thrombocytopenia, and interactions affecting coagulation pathways. Optimal management of these medications encompasses careful baseline cardiovascular and bleeding risk assessments, proactive modification of modifiable risk factors, and vigilant patient monitoring. Prophylactic antithrombotic therapy necessitates cautious individualised evaluation and comprehensive patient monitoring strategies. TKIs exemplify the advancements in precision oncology but necessitate nuanced management of their complex vascular toxicities. A multidisciplinary cardio-oncology approach involving detailed patient education, robust risk stratification, and collaborative clinical management is essential. Future research should aim to clarify TKI-specific haemostatic mechanisms and develop predictive biomarkers, enabling tailored therapeutic strategies to optimise clinical outcomes and reduce adverse events..</p>","PeriodicalId":17546,"journal":{"name":"Journal of Thrombosis and Thrombolysis","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145065032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of viscoelastic testing in the transfusion management of burn patients: a scoping review.","authors":"Mariana Garay Álvarez, Giovanni Rodríguez Rojas, María Alejandra Triana Sutachan, Erwin Hernando Hernández Rincón","doi":"10.1007/s11239-025-03173-4","DOIUrl":"https://doi.org/10.1007/s11239-025-03173-4","url":null,"abstract":"<p><p>Severe burns cause complex hemostatic alterations that complicate transfusion management. Conventional coagulation tests (CCTs) have limitations in timely and accurately assessing these disorders. Viscoelastic tests (VETs), such as thromboelastography (TEG) and rotational thromboelastometry (ROTEM), allow for a dynamic and real-time evaluation of coagulation. A scoping review was conducted following the Arksey and O'Malley methodology and PRISMA-ScR guidelines. Studies from 2010 to 2025 in English or Spanish that evaluated the use of VETs in burn patients were included. Databases such as PubMed, Scopus, and ScienceDirect were analyzed. Eighteen studies were included, mostly narrative reviews and observational studies. ROTEM was the most reported test. VETs were mainly used at admission and intraoperatively. Evidence indicates that TEG and ROTEM outperform CCTs in sensitivity, specificity, and speed, allowing for reduced transfusions and detection of both hypocoagulability and hypercoagulability. VETs are promising tools for transfusion management in burn patients. Although their use is not yet standardized, they offer significant advantages over CCTs and promote more accurate clinical decisions. More studies are needed to support their systematic implementation.</p>","PeriodicalId":17546,"journal":{"name":"Journal of Thrombosis and Thrombolysis","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145033629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of sonothrombolysis as an adjunct to primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: a systematic review and meta-analysis.","authors":"Mohamed Abo Zeid, Ahmed Farid Gadelmawla, Kareem Khalefa, Ahmed Yasser Shaban","doi":"10.1007/s11239-025-03176-1","DOIUrl":"https://doi.org/10.1007/s11239-025-03176-1","url":null,"abstract":"<p><p>In this review, we aimed to evaluate Sonothrombolysis when combined with primary percutaneous coronary intervention (pPCI) in STEMI patients with regard to improving cardiac function and clinical outcomes. This study primarily assesses short-term efficacy outcomes, while long-term impacts, such as mortality, were not evaluated. Following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, we searched four electronic databases (PubMed, Scopus, Cochrane Library, and Web of Science) to identify eligible studies reported up to November 2024. Four studies, with a total population of 252 participants, were included. The sonothrombolysis group demonstrated an overall greater improvement in left ventricular ejection fraction compared to the control group (MD = 3.07, 95% CI [1.20 to 4.94], p = 0.001), with no heterogeneity (p = 0.44, I² = 0%). When subgrouped according to the follow-up period, there was no significant difference between the two groups (MD = 2.56, 95% CI [-0.35 to 5.46]) after 2 to 6 months. Infarction size, microvascular obstruction, left ventricular end-diastolic volume, and left ventricular end-systolic volume showed no statistically significant difference between the two groups. Sonothrombolysis following pPCI is associated with better left ventricular ejection fraction, emphasizing the potential role of sonothrombolysis as an adjunctive therapy to pPCI in the management of STEMI.</p>","PeriodicalId":17546,"journal":{"name":"Journal of Thrombosis and Thrombolysis","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145023606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The inhibitory effect of antiplatelet drugs on spontaneous platelet aggregation on glass surfaces: an analysis based on microscopic three-dimensional topography.","authors":"Yingxia Wu, Ling Ding, Yemei Shen, Xuemei Gao, Dan Chen, Xiaojing Huang, Yuan Li","doi":"10.1007/s11239-025-03177-0","DOIUrl":"https://doi.org/10.1007/s11239-025-03177-0","url":null,"abstract":"<p><p>In vitro assessment of the inhibitory effect of antiplatelet drugs on platelet aggregation is frequently employed to guide personalized antiplatelet therapy in clinical practice. However, existing methods for detecting platelet aggregation rely heavily on high concentrations of exogenous agonists, which may obscure part of the inhibitory effect of antiplatelet drugs and lead to an underestimation of their effects. This study validates a novel analytical strategy for evaluating the effects of antiplatelet drugs by quantifying the microscopic three-dimensional morphological parameters of platelet aggregates formed through spontaneous aggregation on a glass surface. Heparin-anticoagulated platelet-rich plasma (PRP) was applied to a glass surface to induce spontaneous platelet aggregation. The microscopic three-dimensional morphology of platelet aggregates was characterized using a laser three-dimensional microscopic imaging system, and platelet aggregation function was assessed based on the volume parameter (Vol) and cross-sectional area parameter (CS-area) of the aggregates. The results demonstrated that platelets could spontaneously aggregate on the glass surface under the participation of plasma proteins and Ca²⁺. Aspirin (80 μM) significantly reduced Vol but had no significant effect on CS-area. Ticagrelor, eptifibatide, and tirofiban dose-dependently decreased both Vol and CS-area. High concentrations of eptifibatide (4 μM) and tirofiban (4 μM) completely inhibited platelet adhesion and aggregation. The combination of aspirin (20 μM) and ticagrelor (0.5 μM) synergistically suppressed platelet aggregation behavior. GPIb-IX-von Willebrand factor (vWF) inhibitors (4 μM) and indomethacin (4 μM) significantly reduced both Vol and CS-area, with a smaller reduction in CS-area compared to Vol. In patients, aspirin alone significantly reduced Vol, while clopidogrel, aspirin combined with clopidogrel, and Xuesaitong significantly decreased both Vol and CS-area. Our novel analytical strategy is capable of distinguishing the pharmacological effects of various antiplatelet agents without the need for exogenous agonists, suggesting that this system may aid in the determination of the appropriate type and dose of the antiplatelet agent in the clinical setting.</p>","PeriodicalId":17546,"journal":{"name":"Journal of Thrombosis and Thrombolysis","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145023577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A 10-year review of iliofemoral deep vein thrombosis - are they more dangerous than their distal counterparts?","authors":"Brandon Lui, Benjamin Wee, Zille Khattak, Jeffrey Lai, Anna Kwok, Cynthia Donarelli, Prahlad Ho, Hui Yin Lim","doi":"10.1007/s11239-025-03170-7","DOIUrl":"https://doi.org/10.1007/s11239-025-03170-7","url":null,"abstract":"<p><p>Iliofemoral deep vein thrombosis (IFDVT) is associated with potential for poor outcomes despite optimal anticoagulation therapy. To characterize the real-world management of IFDVT in an Australian population. Retrospective evaluation of IFDVT cases managed at Northern Health, Australia from January 2011 to December 2020 was performed and compared to non-iliofemoral lower limb DVTs (non-IFDVT) (n = 1793). 375 IFDVT episodes (median age 69 years; 54.7% female (n = 205)) were diagnosed with median follow-up 56 months. 61.6% (n = 231) were provoked events, including 100 episodes (26.7%) of cancer-associated thrombosis. 24.8% (n = 93) of patients had concomitant pulmonary embolism. Eleven cases underwent endovascular intervention including all seven patients with May-Thurner syndrome. Non-cancer patients with IFDVT received longer duration of anticoagulation (8 vs. 6 months, p < 0.001) or indefinite anticoagulation (28.7% vs. 16.0%, p < 0.001) compared to those with non-IFDVTs. Venous thromboembolism (VTE) recurrence (2.3/100PY, HR 0.839, 95% CI 0.562-1.255, p = 0.390) and major bleeding (2.7/100PY, HR 1.679, 95% CI: 0.876-3.220, p = 0.119) were comparable but the 30-day all-cause mortality (5.1% vs. 1.2%, p < 0.001) including thrombosis-related deaths (1.8% vs. 0.4%, p = 0.004) was more common in the non-cancer IFDVTs. In cancer patients, VTE recurrence rate (4.3/100PY, p = 0.421) was similar but major bleeding (12.4/100PY, p = 0.043) and 30-day mortality (23.0%, p = 0.026) was higher compared to IFDVT patients without active cancer. While the VTE recurrence and major bleeding were comparable between patients with IFDVT and non-IFDVTs, 30-day mortality (including thrombosis-related death) was higher in patients with IFDVT, suggesting a higher risk cohort that warrants careful assessment particularly during the acute period post diagnosis.</p>","PeriodicalId":17546,"journal":{"name":"Journal of Thrombosis and Thrombolysis","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145006349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}